🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Asasantin ER

Found 10 matching trials

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

PHASE1

Study to establish the bioequivalence of a new formulation of Asasantin ER ...

Status

Completed

Location

Multiple Locations

Start Date

2004-01

Trial ID

NCT02273531

Treatments Being Tested

Asasantin ER, new formulation Asasantin ER, present commercial formulation

Tolerability of Asasantin in Healthy Female and Male Subjects

PHASE1

To investigate the occurrence of dipyridamole associated headaches in healt...

Status

Completed

Location

Multiple Locations

Start Date

2000-02

Trial ID

NCT02269228

Treatments Being Tested

Asasantin ER Placebo

Aggrenox To Treat Acute Covid-19

PHASE3

The purpose of this study is to explore the efficacy of Aggrenox in patient...

Status

Completed

Location

Rutgers New Jersey Medical School University Hospital

Start Date

2020-10-21

Trial ID

NCT04410328

Treatments Being Tested

Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care Standard of care

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

PHASE1

To investigate the relative bioavailability of telmisartan respectively of ...

Status

Completed

Location

Multiple Locations

Start Date

2004-05

Trial ID

NCT02262793

Treatments Being Tested

telmisartan ASA/ER-DP

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

PHASE4

German stroke units are hesitating to use Aggrenox for secondary ischaemic ...

Status

Completed

Location

9.182.1 Boehringer Ingelheim Investigational Site

Start Date

2007-07

Trial ID

NCT00562588

Treatments Being Tested

Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)ASA 100 mg qd

Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects

PHASE1

Comparative pharmacokinetics and pharmacodynamics of Asasantin ER at fasted...

Status

Completed

Location

Multiple Locations

Start Date

1999-08

Trial ID

NCT02273492

Treatments Being Tested

Asasantin ER Standardized breakfast

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

PHASE1

Comparative pharmacokinetics of dipyridamole in two new formulations of Asa...

Status

Completed

Location

Multiple Locations

Start Date

2001-04

Trial ID

NCT02273518

Treatments Being Tested

Asasantin ER, new formulation I Asasantin ER, new formulation II Asasantin ER, present commercial formulation

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

PHASE1

The objective of this study was to compare the pharmacokinetics of dipyrida...

Status

Completed

Location

Multiple Locations

Start Date

2003-01

Trial ID

NCT02273557

Treatments Being Tested

Asasantin ER (new formulation I - low)Asasantin ER (new formulation III - medium)Asasantin ER (new formulation II - high)Asasantin ER (present commercial formulation)

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

PHASE1

Comparative Pharmacokinetics of Asasantin Extended Release (ER) and of imme...

Status

Completed

Location

Multiple Locations

Start Date

2000-04

Trial ID

NCT02273505

Treatments Being Tested

Asasantin (ER)Persantin Acetyl salicylic acid (ASA)

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

PHASE1

The objective of this study was to compare the pharmacokinetics of dipyrida...

Status

Terminated

Location

Multiple Locations

Start Date

2002-09

Trial ID

NCT02273544

Treatments Being Tested

Asasantin ER (new formulation - low)Asasantin ER (new formulation - medium)Asasantin ER (new formulation - high)Asasantin ER - commercial formulation

Previous Next